FGF19 and hepatocellular carcinoma: 11q13 was found amplified in 14% of 89 HCC samples and 12 HCC cell lines as reported by Sawey et al. and RNAi-mediated knockdown of Cyclin D1 or FGF19 as well as use of a neutralizing FGF19 antibody resulted in tumour growth inhibition in vitro [44].